Results 1 to 10 of about 25,910 (264)

Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer [PDF]

Frontiers in Immunology, 2023
The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to ...
Xin Zhang, Zheng Xu, Xiangpeng Dai, Xiangpeng Dai, Xiaoling Zhang, Xiaoling Zhang, Xueju Wang   +6 more
doaj   +2 more sources

Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation [PDF]

Genome Medicine, 2021
Background Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized cancer immunotherapies. DNA vaccines can be rapidly and efficiently manufactured and can
Lijin Li, Xiuli Zhang, Xiaoli Wang, Samuel W. Kim, John M. Herndon, Michelle K. Becker-Hapak, Beatriz M. Carreno, Nancy B. Myers, Mark A. Sturmoski, Michael D. McLellan, Christopher A. Miller, Tanner M. Johanns, Benjamin R. Tan, Gavin P. Dunn, Timothy P. Fleming, Ted H. Hansen, S. Peter Goedegebuure, William E. Gillanders   +17 more
doaj   +2 more sources

Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2

Pathogens, 2021
Through 4 June 2021, COVID-19 has caused over 172.84 million cases of infection and 3.71 million deaths worldwide. Due to its rapid dissemination and high mutation rate, it is essential to develop a vaccine harboring multiple epitopes and efficacious ...
Ye Feng, Haiping Jiang, Min Qiu, Liang Liu, Shengmei Zou, Yun Li, Qianpeng Guo, Ning Han, Yingqiang Sun, Kui Wang, Lantian Lu, Xinlei Zhuang, Shanshan Zhang, Shuqing Chen, Fan Mo   +14 more
doaj   +1 more source

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment

Frontiers in Immunology, 2021
BackgroundNeoantigens are critical targets to elicit robust antitumor T-cell responses. Personalized cancer vaccines developed based on neoantigens have shown promising results by prolonging cancer patients’ overall survival (OS) for several cancer types.
Zheling Chen, Shanshan Zhang, Shanshan Zhang, Ning Han, Jiahong Jiang, Yunyun Xu, Dongying Ma, Lantian Lu, Xiaojie Guo, Min Qiu, Qinxue Huang, Huimin Wang, Fan Mo, Fan Mo, Fan Mo, Fan Mo, Shuqing Chen, Shuqing Chen, Shuqing Chen, Liu Yang   +19 more
doaj   +1 more source

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy

Frontiers in Immunology, 2022
BackgroundThe safety and immunogenicity of a personalized neoantigen-based peptide vaccine, iNeo-Vac-P01, was reported previously in patients with a variety of cancer types.
Jiawei Shou, Fan Mo, Fan Mo, Fan Mo, Fan Mo, Shanshan Zhang, Shanshan Zhang, Lantian Lu, Lantian Lu, Ning Han, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Shuqing Chen, Shuqing Chen, Shuqing Chen, Yong Fang   +26 more
doaj   +1 more source

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer

Frontiers in Immunology, 2022
BackgroundCancer neoantigens are important targets of cancer immunotherapy and neoantigen vaccines are currently in development in pancreatic ductal adenocarcinoma (PDAC) and other cancer types. Immune regulatory mechanisms in pancreatic cancer may limit
Hui Peng, Lijin Li, Chong Zuo, Michael Y. Chen, Xiuli Zhang, Nancy B. Myers, Graham D. Hogg, David G. DeNardo, David G. DeNardo, S. Peter Goedegebuure, S. Peter Goedegebuure, William G. Hawkins, William G. Hawkins, William E. Gillanders, William E. Gillanders   +14 more
doaj   +1 more source

Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine

Frontiers in Immunology, 2023
Neoantigens/ are tumor-specific antigens that evade central immune tolerance mechanisms in the thymus. Long-term tumor-specific cytotoxic T lymphocyte activity maintenance requires class II antigen-reactive CD4+ T cells.
Shinji Morisaki, Shinji Morisaki, Shinji Morisaki, Hideya Onishi, Takafumi Morisaki, Makoto Kubo, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Sachiko Yoshimura, Poh Yin Yew, Kazuma Kiyotani, Yusuke Nakamura, Masafumi Nakamura, Takanari Kitazono, Takashi Morisaki   +17 more
doaj   +1 more source

Neoantigens elicit T cell responses in breast cancer

Scientific Reports, 2021
Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells. However, their effect on immune responses in the tumour microenvironment remains unclear in breast cancer.
Takafumi Morisaki, Makoto Kubo, Masayo Umebayashi, Poh Yin Yew, Sachiko Yoshimura, Jae-Hyun Park, Kazuma Kiyotani, Masaya Kai, Mai Yamada, Yoshinao Oda, Yusuke Nakamura, Takashi Morisaki, Masafumi Nakamura   +12 more
doaj   +1 more source

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Journal for ImmunoTherapy of Cancer, 2023
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors.
Shari Pilon-Thomas, Daniel Abate-Daga, Amod A. Sarnaik, James J. Mule, Xiaoqing Yu, Patrick Innamarato, Jamie Blauvelt, Holly Branthoover, Jake Ceccarelli, TJ Langer, MacLean S. Hall, Jamie K. Teer, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Amy M. Hall, Carolyn J. Rich, Allison D. Richards, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, John E. Mullinax   +24 more
doaj   +1 more source

Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests

Journal for ImmunoTherapy of Cancer, 2023
Background Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease.
Steven A Rosenberg, Paul Robbins, Biman Paria, Jared J Gartner, Sri Krishna, Satyajit Ray, Rami Yossef, Victoria Hill, Frank J Lowery, Praveen D Chatani, Neilesh B Parikh, Kyle J Hitscherich, Maria Florentin, Alakesh Bera, Maria Parkhust   +14 more
doaj   +1 more source